https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=1429&f=G&l=50&d=PTXT&p=29&S1=20210720&OS=20210720&RS=20210720
GT Biopharma Announces Updated Safety Data From Phase 1 GTB-3550 Monotherapy TriKE Trial An Investigational Immunotherapy For Refractory Cancers To Be Presented at ESMO Congress 2021
GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager,
